Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
03/18/19vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 18, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common S... 
Printer Friendly Version
02/27/19vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 27, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential of azeliragon in patients with mild-Alzheimer’s Disease (AD) and type 2 diabetes and our progress to date with our Simplici-T1 trial in type 1 dia... 
Printer Friendly Version
01/16/19vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase (GK) activa... 
Printer Friendly Version